10th September 2024
Latest news
Find all of our recent press releases, stay updated with the latest news and be informed about upcoming events where Curium will be attending.
Please direct any media inquiries to: communications@curiumpharma.com
17th June 2024
Curium Continues to Make Strong Progress in European roll-out of Pylclari® – ¹⁸F-PSMA PET Diagnostics of Patients With Prostate Cancer
5th June 2024
Curium adds the Institut Laue–Langevin reactor to global irradiation portfolio to ensure continuous supply of Lutetium-177 benefit more than 100,000 cancer patients over the next 5 years
30th May 2024
Curium Announces First Commercial Doses in France of Pylclari® – an Innovative 18F-PSMA PET Tracer Indicated in Patients With Prostate Cancer
29th May 2024
Curium extends irradiation partnership with NRG | Pallas in Netherlands for continuous supply of Lutetium-177 to treat 1,000s of cancer patients each year
6th May 2024
Curium announces first commercial doses in Germany of PYLCLARI® – an innovative 18F-PSMA PET tracer indicated in patients with prostate cancer
23rd April 2024
Curium Enrolls First Prostate Cancer Patients in its Phase 3 SOLAR Trials
8th April 2024
Curium plans to significantly expand Lutetium-177 capacity and PET footprint with agreement to acquire Eczacibaşi-Monrol
19th March 2024
Curium announces first commercial doses in the Netherlands of PYLCLARI® – an innovative 18F-PSMA PET tracer indicated in patients with prostate cancer
7th March 2024
Curium announces first commercial doses in Italy of PYLCLARI® – an innovative 18F-PSMA PET tracer indicated in patients with prostate cancer
21st February 2024
Curium announces submission of the marketing authorization application for PYLCLARI®, an innovative (18F)-PSMA PET tracer indicated in adults with prostate cancer to Swissmedic
6th February 2024
Curium Announces Ioflupane I 123 Injection Availability for Friday Patient Use
21st November 2023
Curium Completes Patient Enrollment of Phase 3 ECLIPSE Trial Ahead of Schedule
16th November 2023
Curium announces first patients in Europe injected with Pylclari® – an innovative 18F-PSMA PET tracer indicated in patients with prostate cancer
25th October 2023
Curium and PIUR IMAGING announce thyroid imaging partnership in Germany to enable tomographic 3D ultrasound solutions
7th September 2023
Curium announces exclusive distribution agreement in Switzerland with b.e. Imaging for PYLCLARI™, an innovative 18F-PSMA PET tracer indicated in adults with prostate cancer
15th August 2023
Curium announces achievement of co-primary endpoints in phase 2 of its phase 1/2 SOLAR clinical trial imaging men with histologically-proven prostate cancer using copper Cu 64 PSMA I&T
28th July 2023
Curium receives marketing authorization in the EU for Pylclari™, an innovative 18F-PSMA PET tracer indicated in adults with prostate cancer
25th July 2023
Curium announces license and development agreement with Lantheus for AI-based PSMA PET software in Europe
21st July 2023